<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anetoderma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anetoderma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Anetoderma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Taraneh Paravar, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1326716233"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Anetoderma, also known as macular atrophy, is an uncommon disorder of elastic tissue that is clinically characterized by wrinkled and atrophic depressions or saccular outpouchings of the skin (<a class="graphic graphic_picture graphicRef67581 graphicRef110644 graphicRef110646" href="/d/graphic/67581.html" rel="external">picture 1A-C</a>). The saccular outpouchings may herniate upon digital pressure. The primary histologic finding is the loss of elastic tissue in the dermis.</p><p>Anetoderma is divided into primary anetoderma and secondary anetoderma, with the former occurring in areas of previously normal skin and the latter developing in areas of prior skin pathology. Primary anetoderma may occur in association with underlying systemic conditions and warrants evaluation for associated disorders. There is no effective treatment for anetoderma.</p><p>The clinical manifestations, diagnosis, and management of anetoderma will be reviewed here. Anetoderma is distinct from atrophoderma of Pasini and Pierini, a disorder characterized by dermal atrophy and well-defined, hyperpigmented, depressed areas of skin. Atrophoderma of Pasini and Pierini is reviewed separately. (See  <a class="medical medical_review" href="/d/html/108709.html" rel="external">"Atrophoderma of Pasini and Pierini"</a>.)</p><p class="headingAnchor" id="H1687491211"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Anetoderma is considered uncommon, and epidemiologic data are limited. The exact prevalence is not known.</p><p>Primary anetoderma tends to present between ages 20 to 40 but may occur at both younger and older ages. There seems to be a female predominance in primary anetoderma.</p><p>The epidemiology of secondary anetoderma reflects that of the causative skin pathology. Other subtypes of anetoderma, including iatrogenic anetoderma of prematurity, congenital anetoderma, and familial anetoderma, present in infancy or childhood [<a href="#rid1">1-3</a>]. (See <a class="local">'Classification'</a> below.)</p><p class="headingAnchor" id="H13052284"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical phenotype of anetoderma consists of well-circumscribed, round or oval, skin-colored or white macules or patches of wrinkled skin (<a class="graphic graphic_picture graphicRef67581 graphicRef110644 graphicRef110646" href="/d/graphic/67581.html" rel="external">picture 1A-C</a>). Anetoderma may appear as atrophic, depressed patches or saccular outpouchings [<a href="#rid1">1,4,5</a>]. With digital palpation of saccular outpouchings, an inward herniation may be appreciated [<a href="#rid1">1</a>].</p><p>The macules and patches of anetoderma may be several millimeters to 1 to 2 centimeters in diameter [<a href="#rid1">1</a>]. There may be few lesions or hundreds. Common sites of involvement include the trunk and proximal extremities. The palms, soles, scalp, and mucosa are usually spared [<a href="#rid6">6</a>]. Anetoderma is generally asymptomatic but may be pruritic.</p><p class="headingAnchor" id="H3115321496"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Anetoderma is subclassified into the following groups [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Primary anetoderma</p><p class="bulletIndent1"><span class="glyph">●</span>Secondary anetoderma</p><p class="bulletIndent1"><span class="glyph">●</span>Iatrogenic anetoderma of prematurity</p><p class="bulletIndent1"><span class="glyph">●</span>Congenital anetoderma</p><p class="bulletIndent1"><span class="glyph">●</span>Familial anetoderma</p><p class="bulletIndent1"><span class="glyph">●</span>Drug-induced anetoderma</p><p></p><p class="headingAnchor" id="H1800340077"><span class="h2">Primary anetoderma</span><span class="headingEndMark"> — </span>Primary anetoderma occurs in areas of previously normal skin. Historically, primary anetoderma was divided into presentations with preceding inflammation (Jadassohn-Pellizzari type), including erythema and urticaria, and presentations without preceding inflammation (Schweninger-Buzzi type) [<a href="#rid4">4,7</a>]. Given that these two subtypes are histologically identical and have a similar prognosis, this classification scheme has mostly been abandoned [<a href="#rid6">6,8</a>].</p><p class="headingAnchor" id="H191585991"><span class="h3">Associated disorders</span><span class="headingEndMark"> — </span>Primary anetoderma has occurred in patients with various systemic conditions and laboratory abnormalities (<a class="graphic graphic_table graphicRef110595" href="/d/graphic/110595.html" rel="external">table 1</a>). Some authors have classified such presentations as secondary anetoderma; however, we reserve the title of secondary anetoderma for anetoderma that develops in the site of pre-existing skin disease (see <a class="local">'Secondary anetoderma'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiphospholipid antibodies </strong>– The most consistently reported association of primary anetoderma is with antiphospholipid antibodies, including anticardiolipin antibodies, lupus anticoagulant antibodies, and anti-beta-2-glycoprotein antibodies [<a href="#rid9">9,10</a>]. Antiphospholipid antibodies in patients with anetoderma have occurred as an isolated finding or in association with other diseases. In a 2001 case report and review of 20 additional published cases of patients with both primary anetoderma and antiphospholipid antibodies, antiphospholipid antibodies occurred as an isolated finding in four patients [<a href="#rid9">9</a>]. The remaining patients also had primary antiphospholipid syndrome, systemic lupus erythematosus (SLE), other autoimmune disorders, or human immunodeficiency virus (HIV) infection.</p><p></p><p class="bulletIndent1">A retrospective chart review of patients with SLE provides support for an association between antiphospholipid antibodies and anetoderma. In the review, 5 of 33 patients (15 percent) with SLE and lupus anticoagulant antibodies had primary anetoderma, compared with none of 37 patients with SLE who were negative for lupus anticoagulant antibodies [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1">The prevalence of antiphospholipid antibodies in patients with primary anetoderma is not known. A retrospective study found primary anetoderma rare among patients with antiphospholipid syndrome; only 4 of 200 consecutive patients (2 percent) with antiphospholipid syndrome had primary anetoderma [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other disorders </strong>– In addition to antiphospholipid antibodies, the occurrence of other conditions in association with anetoderma is documented in case reports or small studies (<a class="graphic graphic_table graphicRef110595" href="/d/graphic/110595.html" rel="external">table 1</a>). Additional data are necessary to clarify the relationship between anetoderma and these conditions.</p><p></p><p class="bulletIndent1">Examples include autoimmune diseases (eg, SLE, Sjögren's disease [<a href="#rid13">13</a>], Addison's disease [<a href="#rid6">6</a>], systemic sclerosis [<a href="#rid14">14,15</a>], vitiligo [<a href="#rid6">6</a>], alopecia areata [<a href="#rid6">6,14</a>]), prothrombotic states (protein C and S deficiency [<a href="#rid16">16</a>], antithrombin III deficiency [<a href="#rid17">17</a>]), cocaine use [<a href="#rid18">18</a>], multiple sclerosis [<a href="#rid6">6</a>], infections (HIV, tuberculosis, Lyme disease [<a href="#rid19">19</a>]), elevated homocysteine levels in the setting of anorexia [<a href="#rid20">20</a>], subcutaneous injections during ovarian stimulation for in vitro fertilization [<a href="#rid21">21</a>], Hodgkin lymphoma [<a href="#rid22">22</a>], and treatment with cabiralizumab (a colony-stimulating factor 1 receptor inhibitor) and <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> (a programmed cell death 1 inhibitor) with irradiation [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1">There may be an association between the presence of antiphospholipid antibodies and the development of anetoderma in HIV-positive patients [<a href="#rid9">9,24</a>].</p><p></p><p class="bulletIndent1">Laboratory abnormalities reported to associate with anetoderma include elevated antinuclear antibodies [<a href="#rid25">25</a>], rheumatoid factor and antithyroid antibodies [<a href="#rid5">5,15</a>], and decreased serum levels of alpha-1 antitrypsin [<a href="#rid26">26</a>].</p><p></p><p class="headingAnchor" id="H1872804249"><span class="h2">Secondary anetoderma</span><span class="headingEndMark"> — </span>Secondary anetoderma is typically defined as anetoderma occurring in areas affected by a prior skin eruption, such as acne, varicella, discoid lupus erythematosus, secondary syphilis, and papular eruption of HIV disease [<a href="#rid24">24,27</a>]. Information regarding associations between skin conditions and anetoderma are primarily derived from case reports. A list of associated skin disorders is provided in a table (<a class="graphic graphic_table graphicRef110600" href="/d/graphic/110600.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H1462299559"><span class="h2">Iatrogenic anetoderma of prematurity</span><span class="headingEndMark"> — </span>Iatrogenic anetoderma of prematurity has occurred in premature infants born between 24 and 32 weeks of pregnancy. Anetoderma appears weeks to months after birth [<a href="#rid28">28,29</a>]. The most common locations for lesion development are sites on the trunk and proximal extremities where monitoring leads, adhesive tape, or gel electrocardiographic electrodes previously were placed. In some cases, purpuric or erosive patches precede the lesions.</p><p>The etiology of iatrogenic anetoderma of prematurity is hypothesized to be either hypoxemia due to pressure on premature skin or traction on the skin during removal of devices. It has been suggested that low birth weight may be more predictive of this condition than gestational age [<a href="#rid30">30</a>]. Avoidance of lead placement at sites of increased pressure (dorsal body when infant is laying supine) may minimize the development of iatrogenic anetoderma of prematurity [<a href="#rid7">7,28,31</a>]. Other helpful measures may include avoidance of electrode placement at cosmetically sensitive areas as well as changing the position of the electrodes [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H3450571209"><span class="h2">Other subtypes</span><span class="headingEndMark"> — </span>Rare subtypes of anetoderma include congenital, familial, and drug-induced anetoderma:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital anetoderma </strong>– Congenital anetoderma manifesting as anetoderma on the trunk of premature infants at the time of birth is documented in case reports [<a href="#rid32">32,33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Familial anetoderma </strong>– Familial anetoderma tends to develop in the first or second decade of life and may occur in association with ocular, neurologic, gastrointestinal, cardiovascular, or bony abnormalities [<a href="#rid34">34</a>]. Autosomal dominant and autosomal recessive patterns of inheritance have been noted [<a href="#rid35">35,36</a>]. Specific inherited syndromes in which anetoderma has been reported include terminal osseous dysplasia with pigmentary defects [<a href="#rid37">37</a>]; metaphyseal dysplasia, anetoderma, and optic atrophy [<a href="#rid32">32</a>]; exostoses with anetoderma and brachydactyly type E [<a href="#rid32">32</a>]; Reed syndrome [<a href="#rid38">38</a>]; and mutations in the citric acid cycle succinate dehydrogenase subunit B [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced anetoderma </strong>– Medication-induced anetoderma has been reported to occur with <a class="drug drug_general" data-topicid="9747" href="/d/drug information/9747.html" rel="external">penicillamine</a> [<a href="#rid6">6</a>].</p><p></p><p class="headingAnchor" id="H862794687"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>The primary finding in anetoderma is a loss or significant reduction of elastic fibers in the dermis (papillary and/or upper- and mid-reticular dermis) as seen with an elastin stain, such as the Verhoeff-van Gieson stain. Fragmentation of the remaining elastic fibers may be seen, which can also be visualized on electron microscopy.</p><p>A perivascular inflammatory infiltrate composed of mostly lymphocytes, but also of histiocytes, plasma cells, eosinophils, and neutrophils, can occur. Of note, the presence or absence of histologic inflammation is not related to clinical findings [<a href="#rid8">8,40</a>]. Elastophagocytosis, or phagocytosis of elastic fibers by macrophages, may be seen [<a href="#rid41">41</a>]. Microthromboses have also been noted [<a href="#rid11">11</a>].</p><p>On immunohistochemistry, a greater loss of elastin has been noted in protruding lesions compared with indented lesions, possibly suggesting a more advanced stage in the former [<a href="#rid42">42</a>].</p><p>Direct immunofluorescence studies may demonstrate a granular or rarely linear band of immune reactants including immunoglobulins M (IgM) and G (IgG) as well as complement at the dermal-epidermal junction. A granular and fibrillar pattern of immune deposits can be seen between collagen fibers in the dermis. Fibrillar deposits of immune reactants, specifically C3, likely correlating with the location of elastic fibers, may be seen in the dermis. Immune reactants have also been noted around dermal blood vessels [<a href="#rid43">43-45</a>]. These direct immunofluorescence results are not specific to anetoderma.</p><p class="headingAnchor" id="H1880665011"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of anetoderma is not clearly understood. Available evidence suggests increased breakdown of elastic fibers may play a primary role. Potential mechanisms for this process include alterations in elastolytic enzyme activity, ischemia, phagocytosis of elastic fibers, and autoimmune and inflammatory processes [<a href="#rid46">46</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Upregulation or decreased inhibition of elastolytic enzyme activity </strong>– Increased elastic fiber breakdown may result from an increase in matrix metalloproteinase (MMP) elastolytic activity and a decrease in inhibition of this process. In support of this theory, increased production of proforms of gelatinase A (MMP-2) and gelatinase B (MMP-9) as well as increased activation of gelatinase A have been found in specimens of anetoderma [<a href="#rid47">47</a>]. Increased production of MMP-2 in lesional skin without an accompanying increase in the production of tissue inhibitors of MMP-2 also has been detected [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1">In addition, in three patients with pilomatricoma with anetoderma-like changes, MMP-9 staining of fibroblasts and inflammatory cells as well as MMP-12 staining of infiltrating cells in the dermis were noted [<a href="#rid49">49</a>]. These changes were not noted in three cases of ordinary pilomatricoma, supporting the role of MMP-9 and, possibly, MMP-12 in anetoderma.</p><p></p><p class="bulletIndent1">A study that found high expression of tissue inhibitor of metalloproteinase (TIMP)-1 and variable expression of TIMP-2 suggests that increases in TIMP levels may be insufficient to suppress the increased MMP levels in anetoderma [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ischemia </strong>– Ischemia may contribute to elastic fiber breakdown. The presence of microthromboses in biopsy specimens of anetoderma, both in patients with and without antiphospholipid antibodies, supports the theory that local ischemia may lead to activation of elastolytic enzymes and degradation of elastic tissue [<a href="#rid26">26</a>]. In iatrogenic anetoderma of prematurity, pressure may be a trigger for hypoxemia and may lead to the degeneration of elastic tissue [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phagocytosis of elastic fibers </strong>– A role for phagocytosis of elastic fibers by macrophages has been suggested based upon the detection of this finding on electron microscopic examination of lesional tissue from a patient with clinical and histologic findings consistent with anetoderma [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoimmune and inflammatory processes </strong>– The association of anetoderma with antiphospholipid antibodies offers support to the theory that autoimmune and inflammatory processes contribute to anetoderma [<a href="#rid16">16</a>]. One theory is that anticardiolipin antibodies lead to endothelial damage or immune complex and complement activation [<a href="#rid24">24,50</a>]. Other theories include the possible cross-reaction between beta-2-glycoprotein and antigens on elastic fibers; this is supported by the presence of immune reactants on elastic fibers on immunofluorescence [<a href="#rid43">43-45</a>].</p><p></p><p class="bulletIndent1">The presence of T lymphocytes in biopsy specimens of anetoderma lends support to an inflammatory component to this process [<a href="#rid46">46</a>].</p><p></p><p>In addition to elastic fiber breakdown, a decrease in the production of elastic fibers may contribute to anetoderma. The finding of reduced expression of fibulin-4, which aids in elastic fiber formation, in tissue specimens from anetoderma compared with specimens from healthy controls [<a href="#rid51">51</a>] suggests that there may be an impairment in elastic fiber assembly.</p><p>A link between citric acid cycle mutations and anetoderma has been proposed [<a href="#rid39">39</a>].</p><p>Theories to explain the development of secondary anetoderma include the release of elastolytic enzymes from the primary inflammatory skin disease [<a href="#rid52">52</a>]. Anetoderma occurring in sites of skin tumors may result from the destruction of elastic fibers by mechanical trauma [<a href="#rid38">38</a>]. (See <a class="local">'Secondary anetoderma'</a> above.)</p><p class="headingAnchor" id="H97301588"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of anetoderma usually can be made with physical examination alone. Examination of the skin demonstrates skin-colored or white, wrinkled and atrophic depressions or saccular outpouchings that may herniate on digital pressure. When the diagnosis is uncertain, a skin biopsy can be performed to confirm the diagnosis and to rule out other elastic tissue disorders. The biopsy must include the mid-dermis. A 4 mm punch biopsy is adequate. (See <a class="local">'Clinical manifestations'</a> above and  <a class="medical medical_review" href="/d/html/5577.html" rel="external">"Skin biopsy techniques", section on 'Punch biopsy'</a> and <a class="local">'Pathology'</a> above.)</p><p>Once a diagnosis of anetoderma is made, the clinician should determine the subtype of anetoderma. The major distinction is between primary and secondary anetoderma. The patient history aids in differentiation. Secondary anetoderma develops in sites of pre-existing skin disease. Therefore, if there was no preceding skin disorder or only mild erythema or urticarial-type lesions were noted at the sites of anetoderma, then the anetoderma is best categorized as primary anetoderma. Attention to the age of onset, family history, and <a class="drug drug_general" data-topicid="9747" href="/d/drug information/9747.html" rel="external">penicillamine</a> use is useful for identifying patients with other subtypes, including iatrogenic anetoderma of prematurity, congenital anetoderma, familial anetoderma, and drug-induced anetoderma. Unlike primary anetoderma, which usually occurs in adults, iatrogenic anetoderma of prematurity, congenital anetoderma, and familial anetoderma first appear in infancy or childhood. (See <a class="local">'Classification'</a> above.)</p><p class="headingAnchor" id="H1692730217"><span class="h1">ADDITIONAL EVALUATION</span><span class="headingEndMark"> — </span>Patients with primary anetoderma and familial anetoderma require evaluation for extracutaneous disorders:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary anetoderma </strong>– Patients with primary anetoderma require an evaluation for associated underlying disease (<a class="graphic graphic_table graphicRef110595" href="/d/graphic/110595.html" rel="external">table 1</a>). A review of systems and physical examination should be performed with particular attention to signs and symptoms of autoimmune disease. (See <a class="local">'Associated disorders'</a> above.)</p><p></p><p class="bulletIndent1">In particular, given the association of primary anetoderma with antiphospholipid antibodies, patients with primary anetoderma should be asked about a history of thrombotic complications, including spontaneous abortions, strokes, deep vein thrombosis, and superficial phlebitis. The physical examination should assess for other findings seen in antiphospholipid syndrome, such as livedo reticularis, livedoid vasculopathy, vasculitis-like lesions, retiform purpura, cutaneous necrosis, superficial thrombophlebitis, and splinter hemorrhages [<a href="#rid25">25,53</a>].</p><p></p><p class="bulletIndent1">Serologic testing for antiphospholipid antibodies is recommended in all patients with primary anetoderma, regardless of a history of thrombotic complications. Testing is typically performed at the time of diagnosis. Further study is necessary to determine the value of subsequent testing for patients who initially test negative; delayed development of antiphospholipid antibodies is documented in a case report [<a href="#rid54">54</a>]. Measures to minimize risk for thrombosis may be indicated for patients with antiphospholipid antibodies [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/4678.html" rel="external">"Diagnosis of antiphospholipid syndrome"</a> and  <a class="medical medical_review" href="/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome"</a>.)</p><p></p><p class="bulletIndent1">The decision to perform tests for other underlying diseases is based upon a suspicion for specific disorders arising from the patient history, review of systems, or physical examination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Familial anetoderma </strong>– Patients with a history that suggests familial anetoderma or with features that suggest an inherited syndrome should be evaluated for signs of ocular, neurologic, gastrointestinal, cardiovascular, and bony abnormalities. (See <a class="local">'Other subtypes'</a> above.)</p><p></p><p class="headingAnchor" id="H2319918956"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of anetoderma consists of elastic tissue disorders characterized by cutaneous atrophy:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mid-dermal elastolysis </strong>– Mid-dermal elastolysis is an acquired disorder characterized by finely wrinkled skin seen in areas of sun exposure, such as the trunk, arms, and lateral neck (<a class="graphic graphic_picture graphicRef110648" href="/d/graphic/110648.html" rel="external">picture 2</a>). Histologically, there is a loss of elastic fibers in the mid-dermis [<a href="#rid4">4,56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Papular elastorrhexis </strong>– Papular elastorrhexis presents with firm, white, nonfollicular papules that are several millimeters in diameter and located on the trunk. Histology demonstrates fragmentation and loss of elastic fibers in the reticular dermis [<a href="#rid4">4,56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perifollicular elastolysis</strong> – Perifollicular elastolysis presents with small, gray or white, wrinkled perifollicular papules found on the neck, earlobes, upper trunk, and arms. Histologic examination demonstrates loss of perifollicular elastic fibers [<a href="#rid4">4,56</a>]. This is considered by some clinicians to be the same entity as papular acne scars [<a href="#rid57">57,58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Papular acne scars </strong>– Papular acne scars are found on the upper part of the trunk and are characterized by small, skin-colored to hypopigmented, noncompressible follicular papules seen in association with acne. Biopsy demonstrates decreased elastic fibers in the dermis and smaller collagen fibers [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pseudoxanthoma elasticum-like papillary dermal elastolysis </strong>– This disorder presents with yellow to skin-colored papules symmetrically distributed over the lateral neck, supraclavicular area, flexural forearms, axilla, and lower abdomen. It is seen most commonly in older adult females. On biopsy there is a loss of elastic fibers in the papillary dermis [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atrophoderma of Pasini and Pierini </strong>– Atrophoderma of Pasini and Pierini presents with large, hyperpigmented, and depressed areas of skin and most often occurs on the trunk or extremities (<a class="graphic graphic_picture graphicRef109162" href="/d/graphic/109162.html" rel="external">picture 3</a>). (See  <a class="medical medical_review" href="/d/html/108709.html" rel="external">"Atrophoderma of Pasini and Pierini"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutis laxa </strong>– Cutis laxa includes both inherited and acquired forms and is characterized by loose sagging skin folds (<a class="graphic graphic_picture graphicRef110649" href="/d/graphic/110649.html" rel="external">picture 4</a>). Pathology demonstrates reduced and fragmented elastic fibers in the dermis [<a href="#rid4">4,56</a>].</p><p></p><p>The differential diagnosis of iatrogenic anetoderma of prematurity and congenital anetoderma includes aplasia cutis congenita, focal dermal hypoplasia, and erosive and vesicular dermatosis. (See  <a class="medical medical_review" href="/d/html/13725.html" rel="external">"Aplasia cutis congenita"</a> and  <a class="medical medical_review" href="/d/html/117132.html" rel="external">"Focal dermal hypoplasia (Goltz syndrome)"</a>.)</p><p class="headingAnchor" id="H251710434"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Anetoderma is a benign, asymptomatic condition without a clear, effective treatment. Therefore, reassurance of the patient is our general course of action for existing lesions. In patients with secondary anetoderma, the primary skin disorder resulting in anetoderma should be treated whenever feasible to minimize risk for the development of new lesions (<a class="graphic graphic_table graphicRef110600" href="/d/graphic/110600.html" rel="external">table 2</a>). Surgical excision can successfully remove affected skin but is not routinely recommended given the resulting scar and the frequent existence of multiple lesions.</p><p>Although there are case reports describing improvement in the appearance of anetoderma with laser therapy, additional data are needed to confirm efficacy prior to a recommendation for routine use. In a case report of a patient who developed anetoderma secondary to Stevens-Johnson syndrome, sites of anetoderma on the lower back showed improved skin texture after treatment with a 10,600 nm carbon dioxide fractional laser system for three sessions at two-month intervals [<a href="#rid59">59</a>]. The mechanism of action may have involved regeneration of elastin fibers [<a href="#rid59">59</a>]. A pinhole carbon dioxide laser treatment also appeared beneficial in the treatment of a child with anetoderma secondary to juvenile xanthogranuloma [<a href="#rid60">60</a>]. In another case report, combination therapy for anetoderma with a 595 nm pulsed-dye laser and a 1550 nm nonablative fractionated laser demonstrated flattening of skin lesions and improved texture after three sessions at three-week intervals [<a href="#rid61">61</a>]. Of note, an increase in elastic fibers was detected after treatment compared with before treatment.</p><p>Medications have mostly been unsuccessful and include intralesional corticosteroids, oral <a class="drug drug_general" data-topicid="9749" href="/d/drug information/9749.html" rel="external">penicillin G</a>, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a>, <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a>, and niacin [<a href="#rid6">6</a>]. Individual case reports of treatment with epsilon-aminocaproic acid (4 g every six hours) [<a href="#rid62">62</a>] as well as <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> (1 mg per day) [<a href="#rid63">63</a>] have described benefit in patients with primary anetoderma with an inflammatory component. Given the paucity of positive efficacy data, we do not treat anetoderma with medication.</p><p>Other therapies with unclear efficacy include use of radiofrequency devices given the finding of increased elastin after radiofrequency treatment as well as rejuvenation procedures such as the use of fillers and chemical peels [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H3300631612"><span class="h1">PROGNOSIS AND FOLLOW-UP</span><span class="headingEndMark"> — </span>Lesions of anetoderma persist and do not resolve.</p><p>Given the association between primary anetoderma and antiphospholipid antibodies and autoimmune diseases, long-term, periodic follow-up of patients with anetoderma to assess for signs and symptoms of hypercoagulability and autoimmunity is prudent. Thrombotic complications in patients with both anetoderma and antiphospholipid antibodies include fetal loss, strokes, deep vein thrombosis, and superficial phlebitis [<a href="#rid9">9,16</a>]. Such complications may occur years after the diagnosis of primary anetoderma [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H284855916"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification </strong>– Anetoderma is an uncommon elastolytic disorder of the skin. The major subtypes of anetoderma are primary anetoderma and secondary anetoderma, with the former occurring in areas of previously normal skin and the latter developing in areas of prior skin pathology. Other subtypes include iatrogenic anetoderma of prematurity, congenital anetoderma, familial anetoderma, and drug-induced anetoderma. (See <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated disorders </strong>– Primary anetoderma has been reported to occur in association with a variety of systemic conditions and laboratory abnormalities (<a class="graphic graphic_table graphicRef110595" href="/d/graphic/110595.html" rel="external">table 1</a>). The most consistently reported association is with antiphospholipid antibodies. Secondary anetoderma has occurred in association with a wide variety of skin conditions. (See <a class="local">'Primary anetoderma'</a> above and <a class="local">'Secondary anetoderma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– Anetoderma is characterized by wrinkled and atrophic depressions or saccular outpouchings of the skin (<a class="graphic graphic_picture graphicRef67581 graphicRef110644 graphicRef110646" href="/d/graphic/67581.html" rel="external">picture 1A-C</a>). The saccular outpouchings may herniate upon digital pressure. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– A diagnosis of anetoderma usually can be made based upon physical examination alone. If the diagnosis is uncertain, a skin biopsy can be performed to confirm the diagnosis. The primary pathologic finding is a loss or significant reduction of elastic fibers in the dermis. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional evaluation </strong>– Once the diagnosis of anetoderma is made, the clinician should determine the subtype of anetoderma. Patients with primary anetoderma require an evaluation for associated underlying disease. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Additional evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– Data on medical and procedural interventions for anetoderma are primarily limited to case reports and are insufficient to confirm efficacy of any therapy. In general, we do not treat anetoderma. For patients with secondary anetoderma, we treat the primary skin disorder to minimize risk for development of new lesions. There are case reports describing cosmetic improvement in anetoderma with laser therapy; however, data are insufficient to recommend routine use of laser treatment. (See <a class="local">'Treatment'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kineston DP, Xia Y, Turiansky GW. Anetoderma: a case report and review of the literature. Cutis 2008; 81:501.</a></li><li><a class="nounderline abstract_t">Aghaei S, Sodaifi M, Aslani FS, Mazharinia N. An unusual presentation of anetoderma: a case report. BMC Dermatol 2004; 4:9.</a></li><li><a class="nounderline abstract_t">Yu HJ, Shin H, Kang MS, Kim JS. A case of primary anetoderma in an infant. Br J Dermatol 2007; 157:1267.</a></li><li><a class="nounderline abstract_t">Emer J, Roberts D, Sidhu H, et al. Generalized Anetoderma after Intravenous Penicillin Therapy for Secondary Syphilis in an HIV Patient. J Clin Aesthet Dermatol 2013; 6:23.</a></li><li><a class="nounderline abstract_t">Staiger H, Saposnik M, Spiner RE, et al. Primary anetoderma: a cutaneous marker of antiphospholipid antibodies. Skinmed 2011; 9:168.</a></li><li><a class="nounderline abstract_t">Venencie PY, Winkelmann RK, Moore BA. Anetoderma. Clinical findings, associations, and long-term follow-up evaluations. Arch Dermatol 1984; 120:1032.</a></li><li><a class="nounderline abstract_t">Prizant TL, Lucky AW, Frieden IJ, et al. Spontaneous atrophic patches in extremely premature infants. Anetoderma of prematurity. Arch Dermatol 1996; 132:671.</a></li><li><a class="nounderline abstract_t">Venencie PY, Winkelmann RK. Histopathologic findings in anetoderma. Arch Dermatol 1984; 120:1040.</a></li><li><a class="nounderline abstract_t">Romaní J, Pérez F, Llobet M, et al. Anetoderma associated with antiphospholipid antibodies: case report and review of the literature. J Eur Acad Dermatol Venereol 2001; 15:175.</a></li><li><a class="nounderline abstract_t">Esquivel-Valerio JA, Cardenas-de la Garza JA, Arvizu-Rivera RI, Galarza-Delgado DA. Disseminated anetoderma associated with antiphospholipid antibodies. Clin Rheumatol 2020; 39:3887.</a></li><li><a class="nounderline abstract_t">Stephansson EA, Niemi KM, Jouhikainen T, et al. Lupus anticoagulant and the skin. A longterm follow-up study of SLE patients with special reference to histopathological findings. Acta Derm Venereol 1991; 71:416.</a></li><li><a class="nounderline abstract_t">Francès C, Niang S, Laffitte E, et al. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum 2005; 52:1785.</a></li><li><a class="nounderline abstract_t">Yélamos O, Barnadas MA, Díaz C, Puig L. Primary anetoderma associated with primary Sjögren syndrome and anticardiolipin antibodies. Actas Dermosifiliogr 2014; 105:99.</a></li><li><a class="nounderline abstract_t">Hodak E, Feuerman H, Molad Y, et al. Primary anetoderma: a cutaneous sign of antiphospholipid antibodies. Lupus 2003; 12:564.</a></li><li><a class="nounderline abstract_t">Hodak E, Shamai-Lubovitz O, David M, et al. Immunologic abnormalities associated with primary anetoderma. Arch Dermatol 1992; 128:799.</a></li><li><a class="nounderline abstract_t">Sparsa A, Piette JC, Wechsler B, et al. Anetoderma and its prothrombotic abnormalities. J Am Acad Dermatol 2003; 49:1008.</a></li><li><a class="nounderline abstract_t">Clark ER, English JC 3rd. Thrombosis-induced ulcerations of the lower legs with coexistent anetoderma due to anti-thrombin III deficiency. J Am Acad Dermatol 2011; 65:880.</a></li><li><a class="nounderline abstract_t">O'Gorman SM, Sheahan K, Collins P. Cocaine, a culprit in anetoderma? Clin Exp Dermatol 2015; 40:695.</a></li><li><a class="nounderline abstract_t">Bauer J, Leitz G, Palmedo G, Hügel H. Anetoderma: another facet of Lyme disease? J Am Acad Dermatol 2003; 48:S86.</a></li><li><a class="nounderline abstract_t">Aroni K, Ioannidis E, Voudouris S, Yapijakis C. Homocysteinemia-associated anetoderma, in a young woman with anorexia nervosa history. Int J Dermatol 2011; 50:343.</a></li><li><a class="nounderline abstract_t">Bellanca S, Musumeci ML, Catalano F, et al. Primary anetoderma in a woman after ovarian stimulations for in vitro fertilization program. JAAD Case Rep 2019; 5:466.</a></li><li><a class="nounderline abstract_t">Pateriya S, Tiwari N, Young J. Anetoderma in a Patient with Newly Diagnosed Hodgkin's Lymphoma. Skinmed 2021; 19:464.</a></li><li><a class="nounderline abstract_t">Dai J, Zha Y, Foster CC, et al. Punctate Anetoderma After Colony-Stimulating Factor 1 Receptor and Programmed Cell Death 1 Blockade With Irradiation: Clinicopathologic Characterization of a Novel Eruption. JAMA Dermatol 2021; 157:998.</a></li><li><a class="nounderline abstract_t">Lindstrom J, Smith KJ, Skelton HG, et al. Increased anticardiolipin antibodies associated with the development of anetoderma in HIV-1 disease. Military Medical Consortium for the Advancement of Retroviral research (MMCARR). Int J Dermatol 1995; 34:408.</a></li><li><a class="nounderline abstract_t">Hodak E, David M. Primary anetoderma and antiphospholipid antibodies--review of the literature. Clin Rev Allergy Immunol 2007; 32:162.</a></li><li><a class="nounderline abstract_t">Stephansson EA, Niemi KM. Antiphospholipid antibodies and anetoderma: are they associated? Dermatology 1995; 191:204.</a></li><li><a class="nounderline abstract_t">de Faria Melo M, de Faria Melo I, Escobar GF. Secondary Anetoderma. JAMA Dermatol 2021.</a></li><li><a class="nounderline abstract_t">Maffeis L, Pugni L, Pietrasanta C, et al. Iatrogenic anetoderma of prematurity: a case report and review of the literature. Case Rep Dermatol Med 2014; 2014:781493.</a></li><li><a class="nounderline abstract_t">Matić A, Prćić S, Matić M. Iatrogenic Anetoderma of Prematurity: A Series of 5 Clinical Cases and Literature Review. Acta Dermatovenerol Croat 2020; 28:70.</a></li><li><a class="nounderline abstract_t">Colditz PB, Dunster KR, Joy GJ, Robertson IM. Anetoderma of prematurity in association with electrocardiographic electrodes. J Am Acad Dermatol 1999; 41:479.</a></li><li><a class="nounderline abstract_t">Goujon E, Beer F, Gay S, et al. Anetoderma of prematurity: an iatrogenic consequence of neonatal intensive care. Arch Dermatol 2010; 146:565.</a></li><li><a class="nounderline abstract_t">Wain EM, Mellerio JE, Robson A, Atherton DJ. Congenital anetoderma in a preterm infant. Pediatr Dermatol 2008; 25:626.</a></li><li><a class="nounderline abstract_t">Zellman GL, Levy ML. Congenital anetoderma in twins. J Am Acad Dermatol 1997; 36:483.</a></li><li><a class="nounderline abstract_t">Fukayama M, Miyagaki T, Akamata K, et al. Japanese familial anetoderma: A report of two cases and review of the published work. J Dermatol 2018; 45:1459.</a></li><li><a class="nounderline abstract_t">Patrizi A, Neri I, Virdi A, et al. Familial anetoderma: a report of two families. Eur J Dermatol 2011; 21:680.</a></li><li><a class="nounderline abstract_t">Karrer S, Szeimies RM, Stolz W, Landthaler M. Primary Anetoderma in children: report of two cases and literature review. Pediatr Dermatol 1996; 13:382.</a></li><li><a class="nounderline abstract_t">Connor CJ, Shchelochkov OA, Ciliberto H. Anetoderma in a patient with terminal osseous dysplasia with pigmentary defects. Am J Med Genet A 2015; 167A:2459.</a></li><li><a class="nounderline abstract_t">Velez MJ, Mesinkovska N, Bergfeld WF. Anetoderma arising in Reed syndrome: a case report and review of the literature. J Cutan Pathol 2015; 42:765.</a></li><li><a class="nounderline abstract_t">Brys AK, Rodriguez-Homs LG, Wennerberg S, et al. Anetoderma Associated With a Succinate Dehydrogenase Gene Mutation: A Potential Link Between Anetoderma and Citric Acid Cycle Mutations. JAMA Dermatol 2019; 155:1317.</a></li><li><a class="nounderline abstract_t">Oikarinen AI, Palatsi R, Adomian GE, et al. Anetoderma: biochemical and ultrastructural demonstration of an elastin defect in the skin of three patients. J Am Acad Dermatol 1984; 11:64.</a></li><li><a class="nounderline abstract_t">Zaki I, Scerri L, Nelson H. Primary anetoderma: phagocytosis of elastic fibres by macrophages. Clin Exp Dermatol 1994; 19:388.</a></li><li><a class="nounderline abstract_t">Kim JE, Sohn KM, Woo YJ, et al. A Clinicoimmunohistopathologic Study of Anetoderma: Is Protruding Type More Advanced in Stage Than Indented Type? J Immunol Res 2016; 2016:4325463.</a></li><li><a class="nounderline abstract_t">Hodak E, Shamai-Lubovitz O, David M, et al. Primary anetoderma associated with a wide spectrum of autoimmune abnormalities. J Am Acad Dermatol 1991; 25:415.</a></li><li><a class="nounderline abstract_t">Bergman R, Friedman-Birnbaum R, Hazaz B, et al. An immunofluorescence study of primary anetoderma. Clin Exp Dermatol 1990; 15:124.</a></li><li><a class="nounderline abstract_t">Kossard S, Kronman KR, Dicken CH, Schroeter AL. Inflammatory macular atrophy: immunofluorescent and ultrastructural findings. J Am Acad Dermatol 1979; 1:325.</a></li><li><a class="nounderline abstract_t">Venencie PY, Winkelmann RK. Monoclonal antibody studies in the skin lesions of patients with anetoderma. Arch Dermatol 1985; 121:747.</a></li><li><a class="nounderline abstract_t">Venencie PY, Bonnefoy A, Gogly B, et al. Increased expression of gelatinases A and B by skin explants from patients with anetoderma. Br J Dermatol 1997; 137:517.</a></li><li><a class="nounderline abstract_t">Ghomrasseni S, Dridi M, Gogly B, et al. Anetoderma: an altered balance between metalloproteinases and tissue inhibitors of metalloproteinases. Am J Dermatopathol 2002; 24:118.</a></li><li><a class="nounderline abstract_t">Motegi SI, Uehara A, Fujiwara C, et al. Pilomatricoma with bullous-like/anetodermic appearance: Possibly associated with matrix metalloproteinases. J Dermatol 2018; 45:505.</a></li><li><a class="nounderline abstract_t">Hunt R, Chu J, Patel R, Sanchez M. Circumscribed lenticular anetoderma in an HIV-infected man with a history of syphilis and lichen planus. Dermatol Online J 2011; 17:2.</a></li><li><a class="nounderline abstract_t">Gambichler T, Reininghaus L, Skrygan M, et al. Fibulin Protein Expression in Mid-dermal Elastolysis and Anetoderma: A Study of 23 Cases. Acta Derm Venereol 2016; 96:708.</a></li><li><a class="nounderline abstract_t">Requena L, González-Guerra E, Angulo J, et al. Anetodermic mycosis fungoides: a new clinicopathological variant of mycosis fungoides. Br J Dermatol 2008; 158:157.</a></li><li><a class="nounderline abstract_t">Thornsberry LA, LoSicco KI, English JC 3rd. The skin and hypercoagulable states. J Am Acad Dermatol 2013; 69:450.</a></li><li><a class="nounderline abstract_t">Xia FD, Hoang MP, Smith GP. Anetoderma before development of antiphospholipid antibodies: delayed development and monitoring of antiphospholipid antibodies in an SLE patient presenting with anetoderma. Dermatol Online J 2017; 23.</a></li><li><a class="nounderline abstract_t">Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011; 20:206.</a></li><li><a class="nounderline abstract_t">Lewis KG, Bercovitch L, Dill SW, Robinson-Bostom L. Acquired disorders of elastic tissue: Part II. decreased elastic tissue. J Am Acad Dermatol 2004; 51:165.</a></li><li><a class="nounderline abstract_t">Verma SB, Nandkumar G. Rediscovering Perifollicular Elastolysis: A Hitherto Undocumented Entity in India. Indian J Dermatol 2015; 60:603.</a></li><li><a class="nounderline abstract_t">Wilson BB, Dent CH, Cooper PH. Papular acne scars. A common cutaneous finding. Arch Dermatol 1990; 126:797.</a></li><li><a class="nounderline abstract_t">Cho S, Jung JY, Lee JH. Treatment of anetoderma occurring after resolution of Stevens-Johnson syndrome using an ablative 10,600-nm carbon dioxide fractional laser. Dermatol Surg 2012; 38:677.</a></li><li><a class="nounderline abstract_t">Lee SM, Kim YJ, Chang SE. Pinhole carbon dioxide laser treatment of secondary anetoderma associated with juvenile xanthogranuloma. Dermatol Surg 2012; 38:1741.</a></li><li><a class="nounderline abstract_t">Wang K, Ross NA, Saedi N. Anetoderma treated with combined 595-nm pulsed-dye laser and 1550-nm non-ablative fractionated laser. J Cosmet Laser Ther 2016; 18:38.</a></li><li><a class="nounderline abstract_t">Reiss F, Linn E. The therapeutic effect of epsilon-aminocaproic acid on anetoderma Jadassohn. Dermatologica 1973; 146:357.</a></li><li><a class="nounderline abstract_t">Braun RP, Borradori L, Chavaz P, et al. Treatment of primary anetoderma with colchicine. J Am Acad Dermatol 1998; 38:1002.</a></li></ol></div><div id="topicVersionRevision">Topic 110076 Version 6.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18666393" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Anetoderma: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15318943" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : An unusual presentation of anetoderma: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17916209" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A case of primary anetoderma in an infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24003347" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Generalized Anetoderma after Intravenous Penicillin Therapy for Secondary Syphilis in an HIV Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21675496" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Primary anetoderma: a cutaneous marker of antiphospholipid antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6465909" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Anetoderma. Clinical findings, associations, and long-term follow-up evaluations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8651717" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Spontaneous atrophic patches in extremely premature infants. Anetoderma of prematurity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6465910" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Histopathologic findings in anetoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11495531" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Anetoderma associated with antiphospholipid antibodies: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32776312" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Disseminated anetoderma associated with antiphospholipid antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1684471" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lupus anticoagulant and the skin. A longterm follow-up study of SLE patients with special reference to histopathological findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15934071" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23477430" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Primary anetoderma associated with primary Sjögren syndrome and anticardiolipin antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12892400" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Primary anetoderma: a cutaneous sign of antiphospholipid antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1599266" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Immunologic abnormalities associated with primary anetoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14639377" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Anetoderma and its prothrombotic abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21920250" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Thrombosis-induced ulcerations of the lower legs with coexistent anetoderma due to anti-thrombin III deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25703260" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cocaine, a culprit in anetoderma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12734487" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Anetoderma: another facet of Lyme disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21342168" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Homocysteinemia-associated anetoderma, in a young woman with anorexia nervosa history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31193004" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Primary anetoderma in a woman after ovarian stimulations for in vitro fertilization program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35022121" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Anetoderma in a Patient with Newly Diagnosed Hodgkin's Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34190956" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Punctate Anetoderma After Colony-Stimulating Factor 1 Receptor and Programmed Cell Death 1 Blockade With Irradiation: Clinicopathologic Characterization of a Novel Eruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7657440" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Increased anticardiolipin antibodies associated with the development of anetoderma in HIV-1 disease. Military Medical Consortium for the Advancement of Retroviral research (MMCARR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17916987" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Primary anetoderma and antiphospholipid antibodies--review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8534938" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Antiphospholipid antibodies and anetoderma: are they associated?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33851962" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Secondary Anetoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25374702" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Iatrogenic anetoderma of prematurity: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32876031" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Iatrogenic Anetoderma of Prematurity: A Series of 5 Clinical Cases and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10459128" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Anetoderma of prematurity in association with electrocardiographic electrodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20479315" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Anetoderma of prematurity: an iatrogenic consequence of neonatal intensive care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19067869" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Congenital anetoderma in a preterm infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9091489" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Congenital anetoderma in twins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30320485" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Japanese familial anetoderma: A report of two cases and review of the published work.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21719400" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Familial anetoderma: a report of two families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8893237" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Primary Anetoderma in children: report of two cases and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26059211" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Anetoderma in a patient with terminal osseous dysplasia with pigmentary defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25950901" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Anetoderma arising in Reed syndrome: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31483444" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Anetoderma Associated With a Succinate Dehydrogenase Gene Mutation: A Potential Link Between Anetoderma and Citric Acid Cycle Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6736354" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Anetoderma: biochemical and ultrastructural demonstration of an elastin defect in the skin of three patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7955494" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Primary anetoderma: phagocytosis of elastic fibres by macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28116317" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A Clinicoimmunohistopathologic Study of Anetoderma: Is Protruding Type More Advanced in Stage Than Indented Type?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1910055" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Primary anetoderma associated with a wide spectrum of autoimmune abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2189605" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : An immunofluorescence study of primary anetoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/389963" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Inflammatory macular atrophy: immunofluorescent and ultrastructural findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3873911" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Monoclonal antibody studies in the skin lesions of patients with anetoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9390325" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Increased expression of gelatinases A and B by skin explants from patients with anetoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11979071" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Anetoderma: an altered balance between metalloproteinases and tissue inhibitors of metalloproteinases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29682830" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pilomatricoma with bullous-like/anetodermic appearance: Possibly associated with matrix metalloproteinases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22031628" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Circumscribed lenticular anetoderma in an HIV-infected man with a history of syphilis and lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26775654" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Fibulin Protein Expression in Mid-dermal Elastolysis and Anetoderma: A Study of 23 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17999702" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Anetodermic mycosis fungoides: a new clinicopathological variant of mycosis fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23582572" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The skin and hypercoagulable states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329518" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Anetoderma before development of antiphospholipid antibodies: delayed development and monitoring of antiphospholipid antibodies in an SLE patient presenting with anetoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21303837" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a task force at the 13th International Congress on antiphospholipid antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15280835" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Acquired disorders of elastic tissue: Part II. decreased elastic tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26677277" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Rediscovering Perifollicular Elastolysis: A Hitherto Undocumented Entity in India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2140672" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Papular acne scars. A common cutaneous finding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22251221" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment of anetoderma occurring after resolution of Stevens-Johnson syndrome using an ablative 10,600-nm carbon dioxide fractional laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22861121" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pinhole carbon dioxide laser treatment of secondary anetoderma associated with juvenile xanthogranuloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25968163" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Anetoderma treated with combined 595-nm pulsed-dye laser and 1550-nm non-ablative fractionated laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4270611" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The therapeutic effect of epsilon-aminocaproic acid on anetoderma Jadassohn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9632017" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Treatment of primary anetoderma with colchicine.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
